CA2284183A1 - Stable solid preparation containing vitamin d3 and tricalcium phosphate - Google Patents
Stable solid preparation containing vitamin d3 and tricalcium phosphate Download PDFInfo
- Publication number
- CA2284183A1 CA2284183A1 CA002284183A CA2284183A CA2284183A1 CA 2284183 A1 CA2284183 A1 CA 2284183A1 CA 002284183 A CA002284183 A CA 002284183A CA 2284183 A CA2284183 A CA 2284183A CA 2284183 A1 CA2284183 A1 CA 2284183A1
- Authority
- CA
- Canada
- Prior art keywords
- vitamin
- tricalcium phosphate
- pharmaceutical preparation
- active form
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a stable solid preparation containing vitamin D3 and tricalcium phosphate in the treatment of osteoporosis and fractures of the femoral neck, vitamin D3 and/or calcium deficiencies as well as Paget's disease.
Description
Pharmaceutical preparation The invention relates to a novel pharmaceutical preparation comprising an active form of vitamin D3 and tricalcium phosphate and which is free of organic solvent residues.
This novel preparation has an improved stability and can be used, for example, for the prevention of osteoporosis, for the treatment of vitamin D3 and/or calcium deficiency states, for the prevention of fractures of the neck of the femur and also for the prevention of Paget's disease.
The invention furthermore relates to a pharma ceutical preparation, characterized in that 100 to 1400 IU of an active form of vitamin D3 and 1000 to 4500 mg of tricalcium phosphate are employed.
1000 to 4500 mg of tricalcium phosphate correspond to 360 to 1640 mg of calcium.
Preferably, 200 to 1200 IU, in particular 400 to 1000 IU, of an active form of vitamin D3 are employed.
Additionally preferably, 1300 to 4000 mg of tricalcium phosphate, in particular 1600 to 3500 mg, are employed The invention furthermore relates to a pharma ceutical preparation, characterized in that it is a solid preparation in the form of powder or granules.
The invention further relates to a pharma-ceutical preparation, characterized in that it is a solid preparation for oral administration once daily, dispensed in sachets or tablets.
The invention also relates to a pharmaceutical preparation, characterized in that it is a suspension which is prepared from powders before taking.
The invention is based on the object of making available novel medicaments in the form of pharma ceutical preparations which have better properties than known medicaments which can be used for the same purposes.
This object was achieved by the discovery of the novel preparation. Surprisingly, it was found that an active form of vitamin D3 can be processed together with tricalcium phosphate to give a combination preparation.
Tricalcium phosphate has the formula Ca3(PO9)2.
As active forms of vitamin D3, those active vitamin D3 forms are in particular preferred in which the active form carries a hydroxyl group in the la-position, e.g. la-hydroxycholecalciferol, 1a, 25-dihydroxycholecalciferol, la, 24-dihydroxychole-calciferol, la, 24, 25-trihydroxycholecalciferol, la-hydroxy-24-oxocholecalciferol, la, 25-dihydroxy-24-oxocholecalciferol, la, 25-dihydroxycholecalciferol-26,23-lactone, la, 25-dihydroxycholecalciferol-26,23-peroxylactone or 26,26,26,27,27,27-hexafluoro-la, 25-dihydroxycholecalciferol. Also preferred are, for example, 25-hydroxycholecalciferol, 24-hydroxychole-calciferol, 24-oxocholecalciferol, 24,25-dihydroxy-cholecalciferol, 25-hydroxy-24-oxocholecalciferol, 25-hydroxycholecalciferol-26,23-lactone or 25-hydroxy-cholecalciferol-26,23-peroxylactone.
Very particularly preferred is la-hydroxy-cholecalciferol. This is also simply called vitamin D3 or cholecalciferol.
EP 0 413 828 and EP 0 702 954 already mention pharmaceutical preparations which contain combinations of vitamin D3 and calcium salts.
EP 0 413 828 claims a pharmaceutical solid preparation of an active form of vitamin D3, comprising an active form of vitamin D3, which is dispersed in an excipient which is readily soluble in an organic solvent, and contains a basic substance. Among the basic substances, tricalcium phosphaae is not mentioned. The basic substance is used for the stabilization of vitamin D3.
EP 0 702 954 describes a pharmaceutical preparation which contains a calcium salt, vitamin D
and at least one boron, copper or magnesium compound.
It is possible for the composition suitable for osteoporosis treatment to contain 1000 to 2500 mg of calcium salt, corresponding to 400 to 1000 mg of calcium.
Tricalcium phosphate is not mentioned as a calcium salt.
On relatively long-term use, the boron and copper compounds mentioned could lead to undesired side effects.
Japanese Patent JP 05255095 describes a com-position which contains a microcrystalline powder of calcium phosphate (hydroxyapatite or calcium tri-phosphate) and, for example, vitamin D3. The subject ends, however, at i.v. administration and use in blood vessels.
As a calcium source, calcium gluconate, lactate or citrate, dibasic calcium phosphate or preferably calcium carbonate are additionally known from the prior art to the person skilled in the art.
In comparison to the prior art, the preparation according to the invention has a surprising stability.
The data on the stability investigation are given in Table I by example of a batch.
EP 0 413 828 discloses results of stability tests on page 5 in Table I.
Surprisingly, it is possible, in contrast to EP 0 413 828, to prepare the composition according to the invention without the use of organic solvents which have the aim of dissolving adherent auxiliaries.
In comparison to the vitamin D3 content of 91%
measured after 30 days at 40°C and 75o rel. humidity, described in EP 0 413 828, page 5, under the same measurement conditions the composition according to the invention still has, although after 13 weeks, a vitamin D3 content of 97 0 .
This novel preparation has an improved stability and can be used, for example, for the prevention of osteoporosis, for the treatment of vitamin D3 and/or calcium deficiency states, for the prevention of fractures of the neck of the femur and also for the prevention of Paget's disease.
The invention furthermore relates to a pharma ceutical preparation, characterized in that 100 to 1400 IU of an active form of vitamin D3 and 1000 to 4500 mg of tricalcium phosphate are employed.
1000 to 4500 mg of tricalcium phosphate correspond to 360 to 1640 mg of calcium.
Preferably, 200 to 1200 IU, in particular 400 to 1000 IU, of an active form of vitamin D3 are employed.
Additionally preferably, 1300 to 4000 mg of tricalcium phosphate, in particular 1600 to 3500 mg, are employed The invention furthermore relates to a pharma ceutical preparation, characterized in that it is a solid preparation in the form of powder or granules.
The invention further relates to a pharma-ceutical preparation, characterized in that it is a solid preparation for oral administration once daily, dispensed in sachets or tablets.
The invention also relates to a pharmaceutical preparation, characterized in that it is a suspension which is prepared from powders before taking.
The invention is based on the object of making available novel medicaments in the form of pharma ceutical preparations which have better properties than known medicaments which can be used for the same purposes.
This object was achieved by the discovery of the novel preparation. Surprisingly, it was found that an active form of vitamin D3 can be processed together with tricalcium phosphate to give a combination preparation.
Tricalcium phosphate has the formula Ca3(PO9)2.
As active forms of vitamin D3, those active vitamin D3 forms are in particular preferred in which the active form carries a hydroxyl group in the la-position, e.g. la-hydroxycholecalciferol, 1a, 25-dihydroxycholecalciferol, la, 24-dihydroxychole-calciferol, la, 24, 25-trihydroxycholecalciferol, la-hydroxy-24-oxocholecalciferol, la, 25-dihydroxy-24-oxocholecalciferol, la, 25-dihydroxycholecalciferol-26,23-lactone, la, 25-dihydroxycholecalciferol-26,23-peroxylactone or 26,26,26,27,27,27-hexafluoro-la, 25-dihydroxycholecalciferol. Also preferred are, for example, 25-hydroxycholecalciferol, 24-hydroxychole-calciferol, 24-oxocholecalciferol, 24,25-dihydroxy-cholecalciferol, 25-hydroxy-24-oxocholecalciferol, 25-hydroxycholecalciferol-26,23-lactone or 25-hydroxy-cholecalciferol-26,23-peroxylactone.
Very particularly preferred is la-hydroxy-cholecalciferol. This is also simply called vitamin D3 or cholecalciferol.
EP 0 413 828 and EP 0 702 954 already mention pharmaceutical preparations which contain combinations of vitamin D3 and calcium salts.
EP 0 413 828 claims a pharmaceutical solid preparation of an active form of vitamin D3, comprising an active form of vitamin D3, which is dispersed in an excipient which is readily soluble in an organic solvent, and contains a basic substance. Among the basic substances, tricalcium phosphaae is not mentioned. The basic substance is used for the stabilization of vitamin D3.
EP 0 702 954 describes a pharmaceutical preparation which contains a calcium salt, vitamin D
and at least one boron, copper or magnesium compound.
It is possible for the composition suitable for osteoporosis treatment to contain 1000 to 2500 mg of calcium salt, corresponding to 400 to 1000 mg of calcium.
Tricalcium phosphate is not mentioned as a calcium salt.
On relatively long-term use, the boron and copper compounds mentioned could lead to undesired side effects.
Japanese Patent JP 05255095 describes a com-position which contains a microcrystalline powder of calcium phosphate (hydroxyapatite or calcium tri-phosphate) and, for example, vitamin D3. The subject ends, however, at i.v. administration and use in blood vessels.
As a calcium source, calcium gluconate, lactate or citrate, dibasic calcium phosphate or preferably calcium carbonate are additionally known from the prior art to the person skilled in the art.
In comparison to the prior art, the preparation according to the invention has a surprising stability.
The data on the stability investigation are given in Table I by example of a batch.
EP 0 413 828 discloses results of stability tests on page 5 in Table I.
Surprisingly, it is possible, in contrast to EP 0 413 828, to prepare the composition according to the invention without the use of organic solvents which have the aim of dissolving adherent auxiliaries.
In comparison to the vitamin D3 content of 91%
measured after 30 days at 40°C and 75o rel. humidity, described in EP 0 413 828, page 5, under the same measurement conditions the composition according to the invention still has, although after 13 weeks, a vitamin D3 content of 97 0 .
Table I
Stability of the batch 41/95; prepared analogously to Example 2 Batch Appearance,Content Breakdown Water Ca pH
No. of 41/95 odour, cholecal- products contentcontent of taste ciferol cholecal- [~] [g]
[I. U.] ciferol Start corresponds918 0.5~ Tc. 1.60 1.18 6.2 25C/60$
rel.
humidity 13 weekscorresponds897 1~ Ts. 1.64 1.19 6.2 26 weekscorresponds879 1.3$ Tc. 1.77 1.19 6.3 0.9$ Ts.
52 weekscorresponds849 1.2$ Tc. 1.95 1.19 6.2 0.6~ Ts.
30C/60$
rel.
humidity 26 weekscorresponds861 1.5~ Tc. 1.17 1.18 6.2 0.6o Ts.
52 weekscorresponds826 1.3o Tc. 1.41 1.19 6.2 0.6a Ts.
40C/75$
rel.
humidity 13 weekscorresponds890 u.d. 1.72 1.19 6.1 X26 weekscorresponds757 0.6% Tc. 1.82 1.19 6.2 u.d.: under detection limit Tc.: Trans-cholecalciferol Ts.: Tachysterol I.U.: International Unit The present invention also relates to a process for the production of a pharmaceutical preparation, characterized in that an active form of vitamin D3 and tricalcium phosphate is brought into a suitable dose form together with at least one solid excipient or auxiliary by mixing.
Preferably, the active form of vitamin D3 is employed in the form of a solid concentrate.
Cholecalciferol concentrates which are preferred are, for example, Duphasol D3-1000~ dry stable or vitamin D3 type 100 CWS~.
Possible excipients and auxiliaries (binders and/or viscosity increasers) are, for example, mannitol, hydroxypropylcellulose, lactose, polyvinyl-pyrrolidone, polyvinyl alcohol, gelatin, starch, crystalline cellulose, hydroxypropylmethylcellulose, ethylcellulose, carboxymethylcellulose, dextrin, lactose, sorbitol, sucrose, talc (magnesium silicate hydrate), kaolin, precipitated calcium carbonate, sodium chloride, titanium oxide, gum arabic and/or xanthan gum.
Suitable flow-regulating agents are, for example, Aerosil.
Further excipients or auxiliaries can be added, such as, for example, binding agents, antioxidants, colourants, lubricants, sweetening agents and/or flavourings.
Preferred antioxidants are, for example, butylhydroxy toluene (BHT), propyl gallate, butylhydroxyanisole (BHA), lecithin, a-tocopherol, hydroquinone, octyl gallate, dodecyl gallate, isoamyl gallate, nordihydroguaiaretiC acid, guaran gum, a-naphthylamine, ethyl protocatechuate, ascorbic acid-stearic acid ester, ascorbic acid palmitate, cysteine hydrochloride, sodium salt of ascorbyl stearate, thioglycerol or thiosorbitol.
Preferred glidants or lubricants are, for example, talc, starch, magnesium and calcium stearate, boric acid, paraffin, cocoa butter, macrogol, leucine or sodium benzoate.
Preferred sweetening agents are, for example, aspartame or saccharin sodium, preferred flavourings are, for example, lemon or orange essence.
As mentioned in Example 1, the preparation process is characterized in that it is achieved, despite high demands on the uniformity of the distribution of the active compound (see Example 2;
20 ug of cholecalciferol in 4.1 g of powder per sachet), by simple mixing, and without spray granulation, which is cost-intensive and has an adverse effect on the stability.
The novel pharmaceutical preparation can be produced by bringing an active form of vitamin D3 and tricalcium phosphate into a suitable dose form together with at least one solid excipient or auxiliary. The preparations thus obtained can be employed as medica ments in human or veterinary medicine, in particular in the prevention of osteoporosis and fractures of the neck of the femur, and in the treatment of vitamin D3 and/or calcium deficiency states as well as for the prevention of Paget's disease. Carrier substances are organic or inorganic substances which are suitable for oral administration and do not react with the com-pounds, for example gelatin, soya lecithin, carbo-hydrates such as lactose, mannitol or starch, magnesium stearate, talc, cellulose. For oral administration, in particular, tablets, coated tablets, capsules, suspen-sions or granules or powders, dispensed in sachets for use in suspension, are used.
The preparations cari contain auxiliaries such as pre-servatives, stabilizing agents and/or wetting agents, emulsifiers, colourants and/or flavourings.
The daily single dose of vitamin D3 and tricalcium phosphate is preferably from approximately 200 to 1200 IU of vitamin D3 and 1200 to 4000 mg of tricalcium phosphate, in particular from approximately 400 to 1000 IU of vitamin D3 and 1600 to 3500 mg of _ 7 _ tricalcium phosphate, very particularly from approximately 700 to 900 IU of vitamin D3 and 3200 to 3500 mg of tricalcium phosphate. Oral administration is preferred.
Very preferred doses contain 400 IU of vitamin D3 and 1650 mg of tricalcium phosphate, or double the amount in each case, i.e. 800 IU of vitamin D3 and 3300 mg of tricalcium phosphate.
The constituents of the novel pharmaceutical preparation are preferably administered combined.
However, they can also be administered individually, at the same time or successively.
The following examples relate to the production and the composition of the pharmaceutical preparation according to the invention:
Example 1:
Cholecalciferol concentrate and sorbitol are sieved and mixed with one another for 30 minutes in a drum mixer (mixture a).
Tricalcium phosphate, colloidal anhydrous silica, hydroxypropylmethylcellulose, gum arabic, gelatin, aspartame and lemon essence are sieved. The components are then mixed with one another for 30 minutes in a drum mixer together with mixture a.
The mixture is sieved once more and then mixed once more.
Alternatively, the mixing of all components can also be carried out in a high-speed mixer.
Example 2:
Cholecalciferol concentrate and lactose are sieved and mixed with one another for 30 minutes in a drum mixer (mixture a).
Tricalcium phosphate, colloidal anhydrous silica, hydroxypropylmethylcellulose, gum arabic, gelatin, aspartame and orange essence are sieved. The components are then mixed with one another for 30 minutes in a drum mixture together with mixture a.
_ 8 _ The mixture is sieved once more and then mixed once more.
Alternatively, the mixing of all components can also be carried out in a high-speed mixer.
Example 3:
Composition of a powder, dispensed into a sachet, for an oral suspension which contains 1.2 g of calcium and 20 ug of vitamin D3:
Cholecalciferol concentrate* 8.0 mg Sorbitol 227 mg Tricalcium phosphate** 3300.0 mg Colloidal anhydrous silica 130.0 mg Hydroxypropylmethylcellulose 150.0 mg Gum arabic 175.0 mg Saccharin sodium salt 10.0 mg Natural lemon essence 100.0 mg 4100.0 mg *
corresponds to 800 IU of cholecalciferol **
corresponds to 1.2 g of calcium Example 4:
Composition of a powder, dispensed into a sachet, for an oral suspension which contains 0.6 g of calcium and 10 ug of vitamin D3:
Cholecalciferol concentrate* 4.0 mg Sorbitol 114.0 mg Tricalcium phosphate** 1650.0 mg Colloidal anhydrous silica 65.0 mg Hydroxypropylmethylcellulose 75.0 mg Xanthan gum 87.0 mg Saccharin sodium salt 5.0 mg Natural lemon essence 50.0 mg 2050.0 mg corresponds to 400 IU of cholecalciferol '* corresponds to 0.6 g of calcium _ g _ Example 5:
Composition of a suspension which contains 1.2 g of calcium and 20 ug of vitamin D3:
Cholecalciferol concentrate* 8.0 mg Sorbitol 227 mg Tricalcium phosphate** 3300.0 mg Colloidal anhydrous silica 130.0 mg Hydroxypropylmethylcellulose 150.0 mg Xanthan gum 175.0 mg Saccharin sodium salt 10.0 mg Natural lemon essence 100.0 mg Purified water 10 ml * corresponds to 800 IU of cholecalciferol **
corresponds to 1.2 g of calcium
Stability of the batch 41/95; prepared analogously to Example 2 Batch Appearance,Content Breakdown Water Ca pH
No. of 41/95 odour, cholecal- products contentcontent of taste ciferol cholecal- [~] [g]
[I. U.] ciferol Start corresponds918 0.5~ Tc. 1.60 1.18 6.2 25C/60$
rel.
humidity 13 weekscorresponds897 1~ Ts. 1.64 1.19 6.2 26 weekscorresponds879 1.3$ Tc. 1.77 1.19 6.3 0.9$ Ts.
52 weekscorresponds849 1.2$ Tc. 1.95 1.19 6.2 0.6~ Ts.
30C/60$
rel.
humidity 26 weekscorresponds861 1.5~ Tc. 1.17 1.18 6.2 0.6o Ts.
52 weekscorresponds826 1.3o Tc. 1.41 1.19 6.2 0.6a Ts.
40C/75$
rel.
humidity 13 weekscorresponds890 u.d. 1.72 1.19 6.1 X26 weekscorresponds757 0.6% Tc. 1.82 1.19 6.2 u.d.: under detection limit Tc.: Trans-cholecalciferol Ts.: Tachysterol I.U.: International Unit The present invention also relates to a process for the production of a pharmaceutical preparation, characterized in that an active form of vitamin D3 and tricalcium phosphate is brought into a suitable dose form together with at least one solid excipient or auxiliary by mixing.
Preferably, the active form of vitamin D3 is employed in the form of a solid concentrate.
Cholecalciferol concentrates which are preferred are, for example, Duphasol D3-1000~ dry stable or vitamin D3 type 100 CWS~.
Possible excipients and auxiliaries (binders and/or viscosity increasers) are, for example, mannitol, hydroxypropylcellulose, lactose, polyvinyl-pyrrolidone, polyvinyl alcohol, gelatin, starch, crystalline cellulose, hydroxypropylmethylcellulose, ethylcellulose, carboxymethylcellulose, dextrin, lactose, sorbitol, sucrose, talc (magnesium silicate hydrate), kaolin, precipitated calcium carbonate, sodium chloride, titanium oxide, gum arabic and/or xanthan gum.
Suitable flow-regulating agents are, for example, Aerosil.
Further excipients or auxiliaries can be added, such as, for example, binding agents, antioxidants, colourants, lubricants, sweetening agents and/or flavourings.
Preferred antioxidants are, for example, butylhydroxy toluene (BHT), propyl gallate, butylhydroxyanisole (BHA), lecithin, a-tocopherol, hydroquinone, octyl gallate, dodecyl gallate, isoamyl gallate, nordihydroguaiaretiC acid, guaran gum, a-naphthylamine, ethyl protocatechuate, ascorbic acid-stearic acid ester, ascorbic acid palmitate, cysteine hydrochloride, sodium salt of ascorbyl stearate, thioglycerol or thiosorbitol.
Preferred glidants or lubricants are, for example, talc, starch, magnesium and calcium stearate, boric acid, paraffin, cocoa butter, macrogol, leucine or sodium benzoate.
Preferred sweetening agents are, for example, aspartame or saccharin sodium, preferred flavourings are, for example, lemon or orange essence.
As mentioned in Example 1, the preparation process is characterized in that it is achieved, despite high demands on the uniformity of the distribution of the active compound (see Example 2;
20 ug of cholecalciferol in 4.1 g of powder per sachet), by simple mixing, and without spray granulation, which is cost-intensive and has an adverse effect on the stability.
The novel pharmaceutical preparation can be produced by bringing an active form of vitamin D3 and tricalcium phosphate into a suitable dose form together with at least one solid excipient or auxiliary. The preparations thus obtained can be employed as medica ments in human or veterinary medicine, in particular in the prevention of osteoporosis and fractures of the neck of the femur, and in the treatment of vitamin D3 and/or calcium deficiency states as well as for the prevention of Paget's disease. Carrier substances are organic or inorganic substances which are suitable for oral administration and do not react with the com-pounds, for example gelatin, soya lecithin, carbo-hydrates such as lactose, mannitol or starch, magnesium stearate, talc, cellulose. For oral administration, in particular, tablets, coated tablets, capsules, suspen-sions or granules or powders, dispensed in sachets for use in suspension, are used.
The preparations cari contain auxiliaries such as pre-servatives, stabilizing agents and/or wetting agents, emulsifiers, colourants and/or flavourings.
The daily single dose of vitamin D3 and tricalcium phosphate is preferably from approximately 200 to 1200 IU of vitamin D3 and 1200 to 4000 mg of tricalcium phosphate, in particular from approximately 400 to 1000 IU of vitamin D3 and 1600 to 3500 mg of _ 7 _ tricalcium phosphate, very particularly from approximately 700 to 900 IU of vitamin D3 and 3200 to 3500 mg of tricalcium phosphate. Oral administration is preferred.
Very preferred doses contain 400 IU of vitamin D3 and 1650 mg of tricalcium phosphate, or double the amount in each case, i.e. 800 IU of vitamin D3 and 3300 mg of tricalcium phosphate.
The constituents of the novel pharmaceutical preparation are preferably administered combined.
However, they can also be administered individually, at the same time or successively.
The following examples relate to the production and the composition of the pharmaceutical preparation according to the invention:
Example 1:
Cholecalciferol concentrate and sorbitol are sieved and mixed with one another for 30 minutes in a drum mixer (mixture a).
Tricalcium phosphate, colloidal anhydrous silica, hydroxypropylmethylcellulose, gum arabic, gelatin, aspartame and lemon essence are sieved. The components are then mixed with one another for 30 minutes in a drum mixer together with mixture a.
The mixture is sieved once more and then mixed once more.
Alternatively, the mixing of all components can also be carried out in a high-speed mixer.
Example 2:
Cholecalciferol concentrate and lactose are sieved and mixed with one another for 30 minutes in a drum mixer (mixture a).
Tricalcium phosphate, colloidal anhydrous silica, hydroxypropylmethylcellulose, gum arabic, gelatin, aspartame and orange essence are sieved. The components are then mixed with one another for 30 minutes in a drum mixture together with mixture a.
_ 8 _ The mixture is sieved once more and then mixed once more.
Alternatively, the mixing of all components can also be carried out in a high-speed mixer.
Example 3:
Composition of a powder, dispensed into a sachet, for an oral suspension which contains 1.2 g of calcium and 20 ug of vitamin D3:
Cholecalciferol concentrate* 8.0 mg Sorbitol 227 mg Tricalcium phosphate** 3300.0 mg Colloidal anhydrous silica 130.0 mg Hydroxypropylmethylcellulose 150.0 mg Gum arabic 175.0 mg Saccharin sodium salt 10.0 mg Natural lemon essence 100.0 mg 4100.0 mg *
corresponds to 800 IU of cholecalciferol **
corresponds to 1.2 g of calcium Example 4:
Composition of a powder, dispensed into a sachet, for an oral suspension which contains 0.6 g of calcium and 10 ug of vitamin D3:
Cholecalciferol concentrate* 4.0 mg Sorbitol 114.0 mg Tricalcium phosphate** 1650.0 mg Colloidal anhydrous silica 65.0 mg Hydroxypropylmethylcellulose 75.0 mg Xanthan gum 87.0 mg Saccharin sodium salt 5.0 mg Natural lemon essence 50.0 mg 2050.0 mg corresponds to 400 IU of cholecalciferol '* corresponds to 0.6 g of calcium _ g _ Example 5:
Composition of a suspension which contains 1.2 g of calcium and 20 ug of vitamin D3:
Cholecalciferol concentrate* 8.0 mg Sorbitol 227 mg Tricalcium phosphate** 3300.0 mg Colloidal anhydrous silica 130.0 mg Hydroxypropylmethylcellulose 150.0 mg Xanthan gum 175.0 mg Saccharin sodium salt 10.0 mg Natural lemon essence 100.0 mg Purified water 10 ml * corresponds to 800 IU of cholecalciferol **
corresponds to 1.2 g of calcium
Claims (8)
1. Pharmaceutical preparation comprising an active form of vitamin D3 and tricalcium phosphate and which is free of organic solvent residues.
2. Pharmaceutical preparation according to Claim 1, characterized in that 100 to 1400 IU of an active form of vitamin D3 and 1000 to 4500 mg of tricalcium phosphate are employed.
3. Pharmaceutical preparation according to Claim 1 or 2, characterized in that it is a solid preparation in the form of powder, tablets or granules.
4. Pharmaceutical preparation according to Claim 1, 2 or 3, characterized in that it is a solid preparation for oral administration once daily, dispensed in sachets or tablets.
5. Pharmaceutical preparation according to Claim 1 or 2, characterized in that it is a suspension which is prepared from powders before taking.
6. Process for the production of a pharmaceutical preparation, characterized in that an active form of vitamin D3 and tricalcium phosphate is brought into a suitable dose form together with at least one solid excipient or auxiliary by mixing.
7. Use of an active form of vitamin D3 and of tricalcium phosphate for the production of a medicament for the prevention of osteoporosis, for the treatment of vitamin D3 and/or calcium deficiency states and for the prevention of Paget's disease.
8. Use of a pharmaceutical preparation comprising an active form of vitamin D3 and tricalcium phosphate for the control of diseases.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19710054.6 | 1997-03-12 | ||
| DE19710054A DE19710054A1 (en) | 1997-03-12 | 1997-03-12 | Pharmaceutical preparation |
| PCT/EP1998/001208 WO1998040085A1 (en) | 1997-03-12 | 1998-03-04 | Stable solid preparation containing vitamin d3 and tricalcium phosphate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2284183A1 true CA2284183A1 (en) | 1998-09-17 |
Family
ID=7823015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002284183A Abandoned CA2284183A1 (en) | 1997-03-12 | 1998-03-04 | Stable solid preparation containing vitamin d3 and tricalcium phosphate |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0969849B1 (en) |
| JP (1) | JP2001515486A (en) |
| KR (1) | KR20000076042A (en) |
| CN (1) | CN1249689A (en) |
| AR (1) | AR010903A1 (en) |
| AT (1) | ATE245425T1 (en) |
| AU (1) | AU730675B2 (en) |
| BR (1) | BR9808233A (en) |
| CA (1) | CA2284183A1 (en) |
| CZ (1) | CZ290991B6 (en) |
| DE (2) | DE19710054A1 (en) |
| DK (1) | DK0969849T3 (en) |
| ES (1) | ES2201460T3 (en) |
| HU (1) | HUP0002928A3 (en) |
| NO (1) | NO994395D0 (en) |
| PL (1) | PL335644A1 (en) |
| PT (1) | PT969849E (en) |
| SK (1) | SK121699A3 (en) |
| WO (1) | WO1998040085A1 (en) |
| ZA (1) | ZA982073B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3042649A1 (en) * | 2015-01-09 | 2016-07-13 | S.B.M. S.r.l. | A composition, comprising tricalcium phosphate and gelatin, for treating dyspepsia and related disorders |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479474B2 (en) * | 1999-07-08 | 2002-11-12 | Wisconsin Alumni Research Foundation | Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis |
| CA2476679A1 (en) * | 2002-02-20 | 2003-08-28 | Teijin Limited | Vitamin d3 derivatives and remedies using the same |
| US7163933B2 (en) | 2002-02-22 | 2007-01-16 | Teijin Limited | Treating agent for Paget's disease of bone |
| ES2393781T3 (en) * | 2003-05-07 | 2012-12-28 | Osteologix A/S | Strontium combinations for the prophylaxis / treatment of cartilage and / or bone conditions |
| TR200900878A2 (en) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Pharmaceutical formulations combined in a single dosage form |
| TR200900880A2 (en) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Pharmaceutical compositions combined in a single dosage form. |
| UA107599C2 (en) | 2010-06-24 | 2015-01-26 | STABILIZED ACTIVE COMPOUND | |
| WO2014158033A1 (en) | 2013-03-27 | 2014-10-02 | Psm Healthcare Limited | Stabilized vitamin d formulations |
| CN105982071A (en) * | 2015-02-05 | 2016-10-05 | 宁志伟 | High-dose vitamin D3 oral preparation recipe |
| CN104800166B (en) * | 2015-04-22 | 2017-11-10 | 青岛正大海尔制药有限公司 | A kind of Alfacalcidol powder and preparation method thereof |
| CN113350374B (en) * | 2021-06-23 | 2022-05-31 | 锦州医科大学 | Preparation method of calcium phosphate and vitamin D composite microcapsule |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2525478B2 (en) * | 1989-03-01 | 1996-08-21 | 帝人株式会社 | Active Vitamin D with improved stability (3) Lower solid preparation |
| JP3147249B2 (en) * | 1992-03-11 | 2001-03-19 | コベルコ建機株式会社 | Control device for traveling pump pressure |
| IL103224A (en) * | 1992-09-18 | 1998-08-16 | Teva Pharma | Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
| US5548203A (en) * | 1994-06-29 | 1996-08-20 | Electric Power Research Institute, Inc. | Capacitor polarity-based var correction controller for resonant line conditions and large amplitude line harmonics |
| FR2724844B1 (en) * | 1994-09-23 | 1997-01-24 | Innothera Lab Sa | VITAMIN-CALCIUM THERAPEUTIC COMBINATION, PROCESS FOR OBTAINING SAME AND USE THEREOF |
| IL115241A (en) * | 1994-09-26 | 2000-08-31 | American Cyanamid Co | Calcium dietary supplement |
-
1997
- 1997-03-12 DE DE19710054A patent/DE19710054A1/en not_active Withdrawn
-
1998
- 1998-03-04 SK SK1216-99A patent/SK121699A3/en unknown
- 1998-03-04 DK DK98910722T patent/DK0969849T3/en active
- 1998-03-04 ES ES98910722T patent/ES2201460T3/en not_active Expired - Lifetime
- 1998-03-04 KR KR1019997008130A patent/KR20000076042A/en not_active Application Discontinuation
- 1998-03-04 CZ CZ19993221A patent/CZ290991B6/en not_active IP Right Cessation
- 1998-03-04 AU AU64997/98A patent/AU730675B2/en not_active Ceased
- 1998-03-04 HU HU0002928A patent/HUP0002928A3/en unknown
- 1998-03-04 DE DE59809085T patent/DE59809085D1/en not_active Expired - Lifetime
- 1998-03-04 EP EP98910722A patent/EP0969849B1/en not_active Expired - Lifetime
- 1998-03-04 WO PCT/EP1998/001208 patent/WO1998040085A1/en active IP Right Grant
- 1998-03-04 PL PL98335644A patent/PL335644A1/en unknown
- 1998-03-04 CA CA002284183A patent/CA2284183A1/en not_active Abandoned
- 1998-03-04 JP JP53916598A patent/JP2001515486A/en active Pending
- 1998-03-04 BR BR9808233-7A patent/BR9808233A/en not_active IP Right Cessation
- 1998-03-04 PT PT98910722T patent/PT969849E/en unknown
- 1998-03-04 CN CN98803171A patent/CN1249689A/en active Pending
- 1998-03-04 AT AT98910722T patent/ATE245425T1/en active
- 1998-03-11 AR ARP980101087A patent/AR010903A1/en not_active Application Discontinuation
- 1998-03-11 ZA ZA982073A patent/ZA982073B/en unknown
-
1999
- 1999-09-10 NO NO994395A patent/NO994395D0/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3042649A1 (en) * | 2015-01-09 | 2016-07-13 | S.B.M. S.r.l. | A composition, comprising tricalcium phosphate and gelatin, for treating dyspepsia and related disorders |
| WO2016110567A1 (en) * | 2015-01-09 | 2016-07-14 | S.B.M. S.R.L. | Composition comprising tricalcium phosphate and gelatin for use in a method for the treatment of dyspepsia and related disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2201460T3 (en) | 2004-03-16 |
| WO1998040085A1 (en) | 1998-09-17 |
| PT969849E (en) | 2003-12-31 |
| JP2001515486A (en) | 2001-09-18 |
| HUP0002928A3 (en) | 2001-04-28 |
| KR20000076042A (en) | 2000-12-26 |
| DK0969849T3 (en) | 2003-11-03 |
| CZ322199A3 (en) | 2000-01-12 |
| AU730675B2 (en) | 2001-03-08 |
| EP0969849A1 (en) | 2000-01-12 |
| NO994395L (en) | 1999-09-10 |
| SK121699A3 (en) | 2000-01-18 |
| CZ290991B6 (en) | 2002-11-13 |
| ATE245425T1 (en) | 2003-08-15 |
| EP0969849B1 (en) | 2003-07-23 |
| BR9808233A (en) | 2000-05-16 |
| ZA982073B (en) | 1998-09-16 |
| PL335644A1 (en) | 2000-05-08 |
| CN1249689A (en) | 2000-04-05 |
| DE59809085D1 (en) | 2003-08-28 |
| NO994395D0 (en) | 1999-09-10 |
| AU6499798A (en) | 1998-09-29 |
| DE19710054A1 (en) | 1998-09-17 |
| HUP0002928A2 (en) | 2001-02-28 |
| AR010903A1 (en) | 2000-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2525478B2 (en) | Active Vitamin D with improved stability (3) Lower solid preparation | |
| JP3589977B2 (en) | Pharmaceutical formulation containing clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
| JP2602947B2 (en) | Diphosphonic acid derivative oral pharmaceutical composition | |
| JP2002527475A (en) | Fumaric acid micro tablets | |
| AU730675B2 (en) | Stable, solid preparation comprising vitamin D3 and tricalcium phosphate | |
| MXPA96005660A (en) | Oral liquid formulations of alendron | |
| HUP0204114A2 (en) | Pharmaceutical parenteral composition containing biphosphonate | |
| EP1356816A1 (en) | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient | |
| NZ242271A (en) | Medicaments containing a vitamin d compound stabilised by a basic substance | |
| NZ536273A (en) | High dose ibandronate formulation | |
| AU3932199A (en) | Pharmaceutical preparation containing levothyroxine sodium | |
| JP2003504384A (en) | Potassium calcium citrate composition and production method | |
| JPH08231394A (en) | Parmaceutical preparation for suppressing bone loss | |
| WO1999000135A1 (en) | Composition comprising vitamin k and vitamin d, for treating or preventing osteoporosis | |
| EP1651191B1 (en) | Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use | |
| JP6374879B2 (en) | Stable pharmaceutical composition for the treatment of osteoporosis | |
| WO2011113965A1 (en) | Pharmaceutical composition in solid form containing isoflavones, a calcium salt and vitamin d3 | |
| JPH01305030A (en) | Composition for treatment of chlamydia trachomatis infection by single intramuscular administration | |
| MXPA99008344A (en) | Stable solid preparation containing vitamin d3 and tricalcium phosphate | |
| JPH0826982A (en) | Preventing and therapeutic agent for osteoporosis | |
| JPH07215878A (en) | Therapeutic agent for osteoporosis and opsteogenetic promoter | |
| WO2013147451A1 (en) | Pharmaceutical composition containing branched chain amino acid, and production method therefor | |
| JPH10509729A (en) | Kit for osteoporosis treatment cycle | |
| WO1998053827A1 (en) | Treatment of osteoporosis | |
| RU2174836C1 (en) | Pharmaceutical composition eliciting analgesic effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |